Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gonadotropin secretory abnormalities.

V S Herman-Bonert1, G D Braunstein

  • 1UCLA School of Medicine.

Endocrinology and Metabolism Clinics of North America
|September 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo.

Oncology letters·2012
Same author

Induction of sodium iodide symporter gene and molecular characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid carcinoma cells.

British journal of cancer·2008
Same author

Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus.

Rheumatology (Oxford, England)·2008
Same author

A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.

The Journal of clinical endocrinology and metabolism·2003
Same author

Treatment of gynecomastia.

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

Reevaluation of the impact of a stringent low-iodine diet on ablation rates in radioiodine treatment of thyroid carcinoma.

Thyroid : official journal of the American Thyroid Association·2001
Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026
Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026
Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026
Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026
Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026
Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026
See all related articles

Systemic disorders can disrupt the neuroendocrine axis, leading to hypogonadism. While the GnRH test can indicate issues, it doesn't differentiate between hypothalamic and pituitary causes of hypogonadism.

Area of Science:

  • Endocrinology
  • Neuroendocrinology
  • Reproductive Medicine

Background:

  • Puberty relies on normal gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) secretion.
  • Systemic disorders can impair the neuroendocrine axis at various levels, resulting in hypogonadism.
  • Distinguishing between hypothalamic and pituitary causes of hypogonadism using GnRH testing is challenging.

Purpose of the Study:

  • To review the normal physiology of puberty and gonadotropin secretion.
  • To explore how systemic disorders affect the neuroendocrine axis and cause hypogonadism.
  • To discuss abnormalities leading to gonadotropin hypersecretion.

Main Methods:

  • Review of normal physiology of puberty.

Related Experiment Videos

  • Analysis of the impact of systemic disorders on the hypothalamic-pituitary-gonadal axis.
  • Examination of diagnostic challenges in differentiating hypogonadism causes.
  • Review of documented cases of gonadotropin hypersecretion.

    • Main Results:

    • Systemic disorders primarily cause hypogonadism, often reversible upon disease management.
    • The GnRH test cannot reliably distinguish between hypothalamic and pituitary origins of hypogonadism.
    • Certain structural pituitary abnormalities allow for definitive localization of the disorder.
    • Ectopic production of FSH and LH remains unconfirmed.
    • The impact of gonadotropin hypersecretion depends on the age of tumor occurrence.

    Conclusions:

    • Hypogonadism due to systemic disorders is frequently reversible.
    • Precise localization of hypogonadism requires identification of structural pituitary abnormalities.
    • Further research is needed to confirm ectopic gonadotropin production.